Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bradley Pharmaceuticals

Executive Summary

Acquires rights to Upshur-Smith Labs' Lubrin OTC vaginal lubricating inserts. Lubrin sales are forecast by Minneapolis- based Upshur-Smith to top $600,000 in 1992. Bradley is obtaining the rights for $1 mil. plus warrants to purchase 60,000 shares of the company's Class A common stock at $4.50 per share. Fairfield, N.J.-based Bradley additionally will pay Upshur-Smith royalties of 4% on the first $500,000 of adjusted sales and 3% thereafter through 1999. The Lubrin contract covers the U.S. and world market excluding Hong Kong, Japan, Australia, Taiwan, Finland and Italy.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS021961

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel